Table A1.
Characteristics of T2D patients in the discovery and validation cohorts
| Parameter | Discovery Cohort | Validation Cohort |
|---|---|---|
| N | 86 | 44 |
| Sex, M/F, n (%) | 29/57 (33.7%/66.3%) |
16/28 (36.4%/63.4%) |
| Age, years | 65 (58; 69) | 65.5 (58.5; 70) |
| Smokers, n (%) | 10 (11.6%) | 5 (11.4%) |
| BMI, kg/m2 | 33.4 (29.4; 37.4) | 33.2 (29.8; 38.9) |
| Diabetes duration, years | 13.5 (11; 17) | 14 (11; 18) |
| CKD−/NA-CKD/A-CKD−/A-CKD+, n | 22/22/21/21 | 11/11/11/11 |
Continuous data are presented as medians (lower quartile; upper quartile), frequencies are presented as number of patient (percentage in a group). BMI: Body mass index; CKD−: The group of individuals with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio (UACR) <3.0 mg/mmol; NA-CKD: Non-albuminuric chronic kidney disease, the group of individuals with eGFR <60 mL/min/1.73 m2 and UACR <3.0 mg/mmol; A-CKD−: Group of patients with eGFR ≥60 mL/min/1.73 m2 and UACR ≥3.0 mg/mmol; A-CKD+: Group of individuals with eGFR <60 mL/min/1.73 m2 and UACR ≥3.0 mg/mmol.